BAY86-5046 (Betaseron), Non Interventional Studies

BETAEVAL - The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®

This study aims to investigate adherence to therapy among patients treated with Betaferon who are using the BETACONNECT autoinjector.

Inclusion Criteria:

• Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome.
• Patients must be on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician.
• Patient and attending physicians must have agreed on the usage of the BETACONNECT auto-injector device
• Written informed consent must be obtained.

Exclusion Criteria:

• Patients receiving any other disease modifying drug.
• Contraindications of Betaferon described in the Summary of Product Characteristics.